Last reviewed · How we verify
AVTX-009 Regimen 2
AVTX-009 Regimen 2 is a small molecule Small molecule drug developed by Avalo Therapeutics, Inc.. It is currently in Phase 2 development for unknown.
AVTX-009 Regimen 2 is a small molecule that targets the molecular target.
AVTX-009 Regimen 2 is a treatment being studied in a clinical trial for patients with moderate to severe Hidradenitis Suppurativa. AVTX-009 Regimen 2 is a small molecule intervention.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AVTX-009 Regimen 2 |
|---|---|
| Sponsor | Avalo Therapeutics, Inc. |
| Drug class | small molecule |
| Target | unknown |
| Modality | Small molecule |
| Therapeutic area | unknown |
| Phase | Phase 2 |
Mechanism of action
AVTX-009 Regimen 2 works by binding to the molecular target, which results in the desired therapeutic effect.
Approved indications
- unknown
Common side effects
- unknown
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AVTX-009 Regimen 2 CI brief — competitive landscape report
- AVTX-009 Regimen 2 updates RSS · CI watch RSS
- Avalo Therapeutics, Inc. portfolio CI
Frequently asked questions about AVTX-009 Regimen 2
What is AVTX-009 Regimen 2?
How does AVTX-009 Regimen 2 work?
What is AVTX-009 Regimen 2 used for?
Who makes AVTX-009 Regimen 2?
What drug class is AVTX-009 Regimen 2 in?
What development phase is AVTX-009 Regimen 2 in?
What are the side effects of AVTX-009 Regimen 2?
What does AVTX-009 Regimen 2 target?
Related
- Drug class: All small molecule drugs
- Target: All drugs targeting unknown
- Manufacturer: Avalo Therapeutics, Inc. — full pipeline
- Therapeutic area: All drugs in unknown
- Indication: Drugs for unknown
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing